

**Triptafen-DA combined therapy for concurrent depression and anxiety :
whitethroat.**

Contributors

Allen & Hanburys

Publication/Creation

London : Allen & Hanburys, 1966.

Persistent URL

<https://wellcomecollection.org/works/kf4cwhgn>

License and attribution


Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).



Wellcome Collection
183 Euston Road
London NW1 2BE UK
T +44 (0)20 7611 8722
E library@wellcomecollection.org
<https://wellcomecollection.org>



WHITETHROAT.



Triptafen-DA

Trade Mark

Combined therapy for concurrent depression and anxiety.

Depression and anxiety are components of a wide range of conditions involving emotional distress. Triptafen-DA provides a simple, effective way of dealing with the many and varied symptoms they can provoke, including lassitude, anorexia, tension and fatigue. Triptafen-DA is a balance of two psychotropic agents—perphenazine the tranquilliser and amitriptyline the antidepressant. Both are well established and well documented; both

combine high efficacy with low incidence of side effects.

Triptafen-DA tablets contain amitriptyline HCl 25mg and perphenazine BP 2mg. The basic NHS cost of 50 tablets is 13/10d.

Full information on request.



Allen & Hanburys Limited
London E2